Cyclic Versus Daily Teriparatide on Bone Mass

Status unconfirmed · Phase 2

Conditions studied: Osteoporosis

In brief

Osteoporosis is a disease that affects millions of individuals in the United States and abroad. It leads to decreased bone mass and causes an increased risk of fracture. This study will compare continuous versus cyclic treatment with teriparatide combined with alendronate, another drug for osteoporosis, or teriparatide alone in women with osteoporosis.

Key facts

Study ID
NCT00668941
Run by
Helen Hayes Hospital
People needed
140
Starts
2005-09-01
Expected to finish
2017-11-01
Last updated by the study team
2017-08-10

Who can join

Age: 45 and older, up to 85. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.